Trinity Biotech (NASDAQ:TRIB) Research Coverage Started at started coverage on shares of Trinity Biotech (NASDAQ:TRIBFree Report) in a research note issued to investors on Wednesday morning. The brokerage issued a buy rating on the stock.

Trinity Biotech Stock Down 0.4 %

Shares of Trinity Biotech stock opened at $2.46 on Wednesday. The stock has a market cap of $18.75 million, a PE ratio of -0.88 and a beta of 1.16. Trinity Biotech has a 12 month low of $1.49 and a 12 month high of $5.50. The business has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $2.17.

Trinity Biotech (NASDAQ:TRIBGet Free Report) last issued its earnings results on Thursday, May 23rd. The company reported ($0.37) earnings per share for the quarter. Analysts expect that Trinity Biotech will post -2.17 EPS for the current fiscal year.

About Trinity Biotech

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

See Also

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with's FREE daily email newsletter.